167 related articles for article (PubMed ID: 29517409)
21. A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia.
Wang S; Li Y; Tang Y; Xie W; Zhang Y; Liu Q
Front Immunol; 2023; 14():1215450. PubMed ID: 37680626
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.
Hara M; Abe T; Sugawara S; Mizushima Y; Hoshi K; Irimajiri S; Hashimoto H; Yoshino S; Matsui N; Nobunaga M; Nakano S
Mod Rheumatol; 2007; 17(1):1-9. PubMed ID: 17278015
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
[TBL] [Abstract][Full Text] [Related]
24. Iguratimod inhibits protein citrullination and inflammation by downregulating NBCe2 in patients with rheumatoid arthritis.
Peng T; Li B; Bi L; Zhang F
Biomed Pharmacother; 2024 May; 174():116551. PubMed ID: 38636399
[TBL] [Abstract][Full Text] [Related]
25. Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
Yoshioka Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Kanda H; Takagi H; Ito T; Kato T; Saito K; Funahashi K; Asai S; Takemoto T; Terabe K; Asai N; Ishiguro N; Kojima T
Mod Rheumatol; 2016; 26(2):169-74. PubMed ID: 26140467
[TBL] [Abstract][Full Text] [Related]
26. Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder.
Nagata H; Kuriyama K; Nishikawa R; Ohshiro M; Yamamoto-Sugitani M; Fujimoto-Hirakawa Y; Matsumoto Y; Iwai T; Tsukamoto T; Mizutani S; Shimura Y; Kobayashi T; Fukuda W; Uchiyama H; Kuroda J
Ann Hematol; 2021 Nov; 100(11):2849-2850. PubMed ID: 34420071
[No Abstract] [Full Text] [Related]
27. Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.
Tokai N; Yoshida S; Kotani T; Yoshikawa A; Kimura Y; Fujiki Y; Matsumura Y; Takeuchi T; Makino S; Arawaka S
PLoS One; 2018; 13(8):e0202601. PubMed ID: 30138480
[TBL] [Abstract][Full Text] [Related]
28. Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
Xia Z; Lyu J; Hou N; Song L; Li X; Liu H
Z Rheumatol; 2016 Oct; 75(8):828-833. PubMed ID: 26508503
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis.
Li J; Mao H; Liang Y; Lu Y; Chen S; Yang N; Shi G
Clin Dev Immunol; 2013; 2013():310628. PubMed ID: 24371446
[TBL] [Abstract][Full Text] [Related]
30. Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction:
Ishiguro N; Shibata K; Yoshimura A; Ikeuchi S; Ishii M
Mod Rheumatol; 2020 Jul; 30(4):633-639. PubMed ID: 31403345
[No Abstract] [Full Text] [Related]
31. Iguratimod attenuates general disease activity and improves lung function in rheumatoid arthritis-associated interstitial lung disease patients.
Shu P; Shao SQ; Cai XN; Zhou DM; Ma H; Lu L; Yin HQ; Yin SL
Eur Rev Med Pharmacol Sci; 2021 Jul; 25(14):4687-4692. PubMed ID: 34337716
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
Wiese MD; Alotaibi N; O'Doherty C; Sorich MJ; Suppiah V; Cleland LG; Proudman SM
Pharmacogenomics J; 2014 Aug; 14(4):350-5. PubMed ID: 24394199
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study.
Mu R; Li C; Li X; Ke Y; Zhao L; Chen L; Wu R; Wu Z; Zuo X; Xie Y; Chen J; Wei W; Liu Y; Li Z; Dai L; Sun L; Liu X; Li Z
Lancet Reg Health West Pac; 2021 May; 10():100128. PubMed ID: 34327344
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacokinetic and Pharmacodynamic Analyses of Drug-Drug Interactions between Iguratimod and Warfarin].
Yamamoto T; Hasegawa K; Onoda M; Tanaka K
Yakugaku Zasshi; 2016; 136(6):905-11. PubMed ID: 27252068
[TBL] [Abstract][Full Text] [Related]
35. Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis.
Okamura K; Yonemoto Y; Suto T; Okura C; Takagishi K
Mod Rheumatol; 2015 Jul; 25(4):534-9. PubMed ID: 25529033
[TBL] [Abstract][Full Text] [Related]
36. Iguratimod Restrains Circulating Follicular Helper T Cell Function by Inhibiting Glucose Metabolism
Bai Z; Lu Z; Liu R; Tang Y; Ye X; Jin M; Wang G; Li X
Front Immunol; 2022; 13():757616. PubMed ID: 35720293
[TBL] [Abstract][Full Text] [Related]
37. Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.
Wang X; Ma C; Li P; Zhao F; Bi L
Clin Rheumatol; 2017 Jun; 36(6):1369-1377. PubMed ID: 28474138
[TBL] [Abstract][Full Text] [Related]
38. Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.
Xie S; Li S; Tian J; Li F
Front Pharmacol; 2020; 11():73. PubMed ID: 32174824
[TBL] [Abstract][Full Text] [Related]
39. Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept.
Arita Y; Taguchi H; Kobayashi M; Tono T; Ohsone Y; Okano Y
Mod Rheumatol; 2018 Nov; 28(6):1041-1043. PubMed ID: 27180974
[TBL] [Abstract][Full Text] [Related]
40. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
Luo Q; Sun Y; Liu W; Qian C; Jin B; Tao F; Gu Y; Wu X; Shen Y; Xu Q
J Immunol; 2013 Nov; 191(10):4969-78. PubMed ID: 24123677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
